Navigation Links
Novavax CEO to Present at Oppenheimer 19th Annual Healthcare Conference
Date:10/29/2008

ROCKVILLE, Md., Oct. 29 /PRNewswire-FirstCall/ -- Novavax, Inc. (Nasdaq: NVAX) a clinical-stage vaccine company, announced today that Dr. Rahul Singhvi, President and Chief Executive Officer, will be presenting at the Oppenheimer 19th Annual Healthcare Conference at 12:00 pm. (EST) on November 4, 2008 at the Waldorf-Astoria Hotel, New York city. Dr. Singhvi will provide an overview of the company's strategy, research and development progress. A link to the live presentation can be accessed via the Company website at http://www.novavax.com. An archive of the presentation will be available one hour after the event on the Novavax website for 90 days.

ABOUT NOVAVAX

Novavax, Inc. (Nasdaq: NVAX) is a clinical stage biotechnology company, creating novel vaccines to address a broad range of infectious diseases worldwide using advanced proprietary virus-like particle (VLP) technology. The Company produces these VLP based, potent, recombinant vaccines utilizing new and efficient manufacturing approaches. Additional information about Novavax is available at http://www.novavax.com and in the Company's various filings with the Securities and Exchange Commission.


'/>"/>
SOURCE Novavax, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. Novavax CEO to Present at BIO CEO & Investor Conference
2. Novavax Enters Into Estrasorb(R) Asset Sale and Supply Agreements with Graceway Pharmaceuticals, LLC
3. Graceway Pharmaceuticals, LLC(TM) Announces Completed Acquisition of All Assets Related to Estrasorb(R) Product Line in North America From Allergan, Inc. (NYSE: AGN) and Novavax, Inc. (Nasdaq: NVAX)
4. Novavax CEO to Present at the World Vaccine Congress 2008
5. Novavax Opens Its First U.S. Vaccine Plant
6. Novavax Announces Release Date of 2008 First Quarter Financial Results and Investor Conference Call
7. Novavax Reports First Quarter 2008 Financial Results
8. Novavax CEO to Present at ACUMENBioFins 5th Annual Global Healthcare Conference
9. Novavax CEO to Present at FBR Capital Markets 12th Annual Spring Investor Conference
10. Novavax CEO to Present at Piper Jaffray Europe Conference, London, UK
11. Novavax to Join Russell 3000 Index
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... PharmaBoardroom,s new report, , Healthcare and Life ... free download , digs deep into this vibrant market, speaking ... today. One area where Algeria ... homegrown pharmaceutical manufacturing base, even if the government,s ambitious target ... A cursory comparison with neighboring Morocco ...
(Date:12/22/2014)... 22, 2014   Synthetic Biologics, Inc. ... pathogen-specific therapies for serious infections and diseases, ... today announced positive topline safety and tolerability ... of SYN-004, the Company,s investigational oral beta-lactamase ... difficile (C. difficile) infection, antibiotic-associated diarrhea ...
(Date:12/22/2014)... (PRWEB) December 22, 2014 ... peer-reviewed publication of original research, reviews and editorials ... and clinical practice, today published a provocative article ... the development, progression and potential treatment of prostate ... endocrinology research and proposes the possibility that there ...
(Date:12/19/2014)... BioPlus Specialty Pharmacy (BioPlus), one of ... Nick Maroulis, Pharm.D. to the newly created position of ... this position, Dr. Maroulis will continue to manage the ... our multi-site pharmacies as the company expands. Dr. Maroulis ... time he has served in many different capacities in ...
Breaking Biology Technology:PharmaBoardroom Releases New Algeria Pharmaceuticals Report 2PharmaBoardroom Releases New Algeria Pharmaceuticals Report 3Synthetic Biologics Announces Positive Topline Results from Phase 1a Trial of SYN-004 for the Prevention of C. difficile Infection 2Synthetic Biologics Announces Positive Topline Results from Phase 1a Trial of SYN-004 for the Prevention of C. difficile Infection 3Synthetic Biologics Announces Positive Topline Results from Phase 1a Trial of SYN-004 for the Prevention of C. difficile Infection 4Synthetic Biologics Announces Positive Topline Results from Phase 1a Trial of SYN-004 for the Prevention of C. difficile Infection 5Prostate Cancer Experts Dissect the Role of Follicle-stimulating Hormone in the Development, Progression and Potential Treatment of Prostate Cancer 2Prostate Cancer Experts Dissect the Role of Follicle-stimulating Hormone in the Development, Progression and Potential Treatment of Prostate Cancer 3Prostate Cancer Experts Dissect the Role of Follicle-stimulating Hormone in the Development, Progression and Potential Treatment of Prostate Cancer 4BioPlus Specialty Pharmacy Promotes Dr. Nick Maroulis to Vice President of Specialty Pharmacy Services 2
... (NYSE: WPI ), a leading specialty pharmaceutical,company, ... chief,executive officer, will provide an overview and update ... Global Pharmaceutical, Biotechnology and,Medical Device Conference on Tuesday, ... This presentation will be webcast live and ...
... 1 Inverness Medical,Innovations, Inc. (Amex: IMA ... release dated January 31, 2008 and entitled "Inverness ... Pharmaceutical,Biotechnology and Medical Device Conference on February 5, ... the Company,s presentation. The,correct time of the presentation ...
... the Highest Level of Clinical Immunology Expertise, ... Genetic,Immunity(R), a US/Hungarian clinical-stage biopharmaceutical company,focused on the ... announced that it has appointed,Richard B. Pollard, M.D. ... been a leader in HIV/AIDS research for more ...
Cached Biology Technology:Genetic Immunity Announces the Appointment of Richard B. Pollard, M.D. as Chief Medical Officer 2Genetic Immunity Announces the Appointment of Richard B. Pollard, M.D. as Chief Medical Officer 3
(Date:12/19/2014)... DUBLIN , Dec. 18, 2014 Research and ... addition of the "Micro Market Monitor: North America ... http://photos.prnewswire.com/prnh/20130307/600769 ... grow at a CAGR of 3.6% from 2014 to ... in this market, Canada is ...
(Date:12/17/2014)... Dec. 15, 2014 Research and Markets ... of the "Samsung Galaxy S5 - Home ... to their offering. ... different sensing technology than the iPhone 5S, Samsung ... in its product. The Galaxy S5 ...
(Date:12/17/2014)... , Dec. 16, 2014 Valencell, a leader ... PerformTek biometric technology to industry leaders such as Intel, ... clinically validated, biometric wearable products. These products will be ... Las Vegas . ... accurate, flexible and robust – with the clinical data ...
Breaking Biology News(10 mins):Micro Market Monitor: North America Perimeter Security Systems Market (Intrusion Detection Sensor, Video Surveillance, Communication/Alarm and Notification, Access Control System) 2Micro Market Monitor: North America Perimeter Security Systems Market (Intrusion Detection Sensor, Video Surveillance, Communication/Alarm and Notification, Access Control System) 3Samsung Galaxy S5 - Home Button Synaptics Fingerprint Sensor Technology Analysis 2Valencell PerformTek Biometrics Power the Most Accurate Wearables at CES 2015 2
... Shenzhen, China - A group of scientists from United Kingdom ... complete sequencing of peregrine and saker falcons genomes at the ... The study is a part of Falcon Genome Project, launched ... in this January. The results will enable biologists to better ...
... therapy may be one step closer, thanks to a new ... of University of Illinois researchers, led by professors Jianjun Cheng ... efficiently deliver DNA segments to cells. The team published its ... main idea is these are new materials that could potentially ...
... to Human H5N1 Infection in China Sequences of ... from patients who had recently visited the live bird markets, ... of Virology . Live poultry markets have long been suspected ... but this is the first molecular evidence linking H5N1 in ...
Cached Biology News:Genomic sequences of 2 iconic falconry birds - Peregrine and Saker Falcons- successfully decoded 2Let's do the twist: Spiral proteins are efficient gene delivery agents 2Let's do the twist: Spiral proteins are efficient gene delivery agents 3Tips from the journals of the American Society for Microbiology 2Tips from the journals of the American Society for Microbiology 3Tips from the journals of the American Society for Microbiology 4Tips from the journals of the American Society for Microbiology 5Tips from the journals of the American Society for Microbiology 6
...
... Monoclonal Anti-β-Tubulin IV Recognizes an ... sequence of β-tubulin isotype IV. ... isotypes is observed. ascites fluid ... C-terminal sequence of β-tubulin isotype ...
... Finnpipette BioControl is a major step ... complete liquid handling system - with ... tip cone modules. All five single ... modules fit one handle. The lightweight ...
... the joining of two strands of DNA ... of adjacent nucleotides in either a cohesive-ended ... also been shown to catalyze the joining ... RNA strand in a duplex molecule but ...
Biology Products: